Delving into the Latest Updates on Finlay Vaccine Institute with Synapse

Phase II-III, controlled, randomized, double-blind, non-inferiority, adaptive and multicenter clinical trial to evaluate the immunogenicity, safety and efficacy of the 11-valent conjugate vaccine candidate against pneumococci (VCN11) in infants - NEUMO11/25

开始日期2024-09-09

申办/合作机构

Finlay Vaccine Institute

RPCEC00000432 / Suspended临床3期IIT

Evaluation of the safety, immunogenicity and clinical effectiveness of the application of the Cuban anti-pneumococcal vaccine candidate PCV7-T, in patients from one to 18 years of age at risk of pneumococcal disease in the province of Havana. Phase III - NRH/24

开始日期2023-10-09

申办/合作机构

Finlay Vaccine Institute

RPCEC00000397 / CompletedN/AIIT

Exploratory study of the SOBERANA Plus ST vaccine, to evaluate its reactogenicity and immunogenicity in adults from Italy: COVID-19 convalescents; and subjects without a history of this disease and previously immunized against SARS-CoV-2. (COVID-19) - SOBERANA PLUS TURIN

开始日期2021-11-16

申办/合作机构

Finlay Vaccine Institute

100 项与 Finlay Vaccine Institute 相关的临床结果

登录后查看更多信息

0 项与 Finlay Vaccine Institute 相关的专利（医药）

登录后查看更多信息

46

项与 Finlay Vaccine Institute 相关的文献（医药）

2024-01-02·Angewandte Chemie International Edition

Diversification of a Novel α‐Galactosyl Ceramide Hotspot Boosts the Adjuvant Properties in Parenteral and Mucosal Vaccines

Article

作者: Yousefi, Mohammad ; Schulze, Kai ; Davari, Mehdi D ; Rivera, Daniel G ; Westermann, Bernhard ; Ebensen, Thomas ; Méndez, Yanira ; Guzmán, Carlos A ; Wessjohann, Ludger A ; Vasco, Aldrin V

AbstractThe development of potent adjuvants is an important step for improving the performance of subunit vaccines. CD1d agonists, such as the prototypical α‐galactosyl ceramide (α‐GalCer), are of special interest due to their ability to activate iNKT cells and trigger rapid dendritic cell maturation and B‐cell activation. Herein, we introduce a novel derivatization hotspot at the α‐GalCer skeleton, namely the N‐substituent at the amide bond. The multicomponent diversification of this previously unexplored glycolipid chemotype space permitted the introduction of a variety of extra functionalities that can either potentiate the adjuvant properties or serve as handles for further conjugation to antigens toward the development of self‐adjuvanting vaccines. This strategy led to the discovery of compounds eliciting enhanced antigen‐specific T cell stimulation and a higher antibody response when delivered by either the parenteral or the mucosal route, as compared to a known potent CD1d agonist. Notably, various functionalized α‐GalCer analogues showed a more potent adjuvant effect after intranasal immunization than a PEGylated α‐GalCer analogue previously optimized for this purpose. Ultimately, this work could open multiple avenues of opportunity for the use of mucosal vaccines against microbial infections.

2023-12-01·Journal of Interferon & Cytokine Research

BioHabana 2022: Preventive and Immunotherapeutic Strategies Against COVID-19 and Cancer in Cuba

Article

作者: Muzio-Gonzalez, Verena ; Aguilera-Barreto, Ana ; Mesa-Pardillo, Circe ; Nodarse-Cuní, Hugo ; Vazquez-Blomquist, Dania ; Bello-Rivero, Iraldo ; Mazorra-Herrera, Zaima ; Guillen-Nieto, Gerardo ; Garcia-Rivera, Dagmar ; Hernández-Bernal, Francisco ; Crombet-Ramos, Tania ; Morera-Díaz, Yanelys ; Domínguez-Horta, Maria Del Carmen

The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversification of the biotechnology, pharmaceutical, and medical technology industries, including the phenomenon of digital transformation, which has given rise to the so-called Fourth Industrial Revolution (Industry 4.0). Confronting the COVID-19 pandemic revealed the outstanding response capacity of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and interinstitutional approach that has achieved an unprecedented integration in the history of biomedical science. Cuba, a small country, with scarce material resources, has had remarkable success in controlling the disease, which also highlights the impact of social factors. This report presents a summary of the most relevant presentations of selected topics during the scientific meeting, "BioHabana 2022: Cancer Immunotherapy and the COVID-19 Pandemic," which was held in Havana Cuba in April 2022.

2023-10-01·Heliyon

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine

Article

作者: Salehi-Vaziri, Mostafa ; Farahmand, Behrokh ; Saberpour, Masoumeh ; Bagheri Amiri, Fahimeh ; Ashrafian, Fatemeh ; Jalali, Tahmineh ; Bavand, Anahita ; Sadat Larijani, Mona ; Eslamifar, Ali ; Noori Daloii, Hassan ; Biglari, Alireza ; Dahmardeh, Sarah ; Verez-Bencomo, Vicente ; Banifazl, Mohammad ; Fotouhi, Fatemeh ; Ramezani, Amitis ; Eshratkhah Mohammadnejad, Azita ; Sorouri, Rahim ; Mostafavi, Ehsan ; Tavakoli, Mahsa

COVID-19 pandemic has been managed through global vaccination programs. However, the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus as a protein subunit vaccine was investigated in immunized health care workers by COVAXIN (BBV152). The booster vaccine was recommended at least three months post the second dose of COVAXIN. Sera collection was done before and after each injection. SARS-CoV-2 PCR test was done monthly to detect any asymptomatic and symptomatic vaccine breakthrough. 47.9 and 24.3% of the participants were seronegative for anti-N and anti-S antibodies three months after the second dose of COVAXIN, respectively. On average, fold-rises of 70, 93, 8 and mean-rises of 23.32, 892.4, 5.59 were recorded regarding neutralizing antibody, quantitative and semi-quantitative anti-Spike antibody, respectively. Anti-Spike and neutralizing antibodies seroconversion was seen 59.3% and 45.7%, respectively. The vaccine breakthrough assessment showed that all the isolated samples belonged to SARS-CoV-2 Delta variant. PastoCovac Plus boosting is strongly recommended in combination with inactivated vaccine platforms against SARS-CoV-2.

100 项与 Finlay Vaccine Institute 相关的药物交易

登录后查看更多信息

100 项与 Finlay Vaccine Institute 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

临床3期

批准上市

2

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Leptospirosis vaccine trivalent (Finlay Institute)	钩端螺旋体病更多	批准上市
Meningococcal vaccine groups B and C(Finlay Institute)	脑膜炎球菌感染更多	批准上市
FINLAY-FR2 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute) ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	临床3期
伤寒结合疫苗(Finlay Institute)	伤寒更多	临床前
FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)	新型冠状病毒感染更多	无进展